Title :

Everolimus or sunitinib as first-line treatment of metastatic papillary renal cell carcinoma: A retrospective study of the GETUG group (Groupe d'Etude des Tumeurs Uro-Génitales)

Author(s) :

Cancel, M. [Auteur]
Fromont, G. [Auteur]
Blonz, C. [Auteur]
Chevreau, C. [Auteur]
Rioux-Leclercq, N. [Auteur]
Laguerre, B. [Auteur]
Oudard, S. [Auteur]
Gross-Goupil, M. [Auteur]
Gravis, G. [Auteur]
Goldwasser, F. [Auteur]
Rolland, F. [Auteur]
Delva, R. [Auteur]
Moise, L. [Auteur]
Emambux, S. [Auteur]
Vassal, C. [Auteur]
Zanetta, S. [Auteur]
Penel, Nicolas [Auteur]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Fléchon, A. [Auteur]
Barthélémy, P. [Auteur]
Saldana, C. [Auteur]
Lefort, F. [Auteur]
Escudier, B. [Auteur]
Linassier, C. [Auteur]
Albiges, L. [Auteur]

Journal title :

European Journal of Cancer

Abbreviated title :

Eur J Cancer

Volume number :

158

Pages :

p. 1-11

Publication date :

2021-11

ISSN :

1879-0852

English keyword(s) :

Papillary renal cell carcinoma
Metastatic
Sunitinib
Everolimus
First-line treatment
Prognostic factors
Real world
IMDC risk groups

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Background Two phase II trials (NCT00688753 and NCT00541008) reported efficacy data of sunitinib and everolimus in first-line treatment of metastatic papillary renal cell carcinoma (mpRCC). Although most patients receive ...
Show more >Background Two phase II trials (NCT00688753 and NCT00541008) reported efficacy data of sunitinib and everolimus in first-line treatment of metastatic papillary renal cell carcinoma (mpRCC). Although most patients receive sunitinib or a mammalian target of rapamycin (mTOR) inhibitor in first- and second-line treatment, the optimal strategy remained unknown. Material and methods In 23 centres of the Groupe d’Etude des Tumeurs Urogénitales group, after centralised pathological review, we analysed retrospectively progression-free survival (PFS) of patients with mpRCC treated in first-line treatment (PFS-1) with sunitinib or everolimus (primary end-point), PFS in second-line treatment (PFS-2), overall survival (OS), objective response rate, disease control rate (DCR), overall sequence and prognostic factors for OS (secondary end-points). Results One hundred thirty-eight patients (119 men and 19 women), median age 62.5 years, with mpRCC type 1 (n = 24) or non–type 1 (n = 114), received first-line sunitinib (n = 107) or everolimus (n = 31). With a median follow-up of 92 months, we found no significant difference between the treatment groups in terms of PFS-1 (5.5 versus 6.2 months) and DCR (69% versus 83%). Ninety-eight patients received a second-line treatment, 69% with mTOR inhibitors after sunitinib and 100% with tyrosine kinase inhibitors after everolimus, with similar DCR (64% versus 58%), median PFS-2 (3.4 versus 4.8 months) and OS (16.0 versus 20.3 months). No factor was prognostic for PFS-1, whereas leukocytosis, anaemia and the time from diagnosis to first systemic therapy < 1 year were prognostic for OS. We found no prognostic difference between both pRCC subtypes. The International Metastatic Renal Cell Database Consortium risk factors were prognostic for OS. Conclusion Sunitinib and everolimus had similar efficacy in first-line treatment of patients with mpRCC.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
CHU Lille

Collections :

• METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

Submission date :

2023-11-15T05:47:14Z
2024-02-14T09:04:12Z